PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP

Summary

This trial is a single-center, prospective, single-arm Phase II clinical study. The purpose is to evaluate the efficacy and safety of recombinant humanized anti-PD-1 monoclonal antibody combined with albumin paclitaxel and bevacizumab in the second-line treatment of patients with unknown primary tumors.

Timeline

Start

2021-05-13

Primary completion

2023-05-01

Completion

2023-05-03

Publications

• Zhang X, Zhao T, Xu M, Guo Y, Wang Q, Wang Y, Zhou L, Hu S, Xu Q, Hu X, Liu X, Luo Z. Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial. Nat Commun. 2026 May 9. doi: 10.1038/s41467-026-72745-6. Online ahead of print.

Drugs

Indications